Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, has been confirmed as keynote speaker at one of the year’s biggest international biotechnology conferences, Bio Japan.
Professor Workman will be representing UK research and showcasing The London Cancer Hub as part of a delegation led by MedCity, which promotes life-science investment, entrepreneurship and industry in London and the South East.
Bio Japan will be held in Yokohama in October and will bring together thousands of delegates from the worldwide life sciences industry, identifying new investment opportunities and partnerships.
In his keynote at Bio Japan, Professor Workman will talk about the vital importance of academic-industry partnerships in discovering and developing new cancer drugs, biomarkers and devices for patients – using past and current examples from the ICR’s own pipeline of innovative cancer treatments.
Discovery and innovation
The ICR is the world’s leading academic centre for cancer drug discovery, having discovered 20 new drug candidates since 2005, of which 10 have entered clinical trials. Many of its greatest successes in the development of new cancer therapies have been in collaboration with industry as well as other non-profit organisations.
At Bio Japan, Professor Workman will introduce the latest developments at The London Cancer Hub, a life-science campus in Sutton, south London, which aims to become the world’s leading centre specifically to focus on integrating cancer research, treatment and education with commercial enterprise.
The ICR recently announced that in spring 2020 it will be opening a £75m Centre for Cancer Drug Discovery, one of the flagship buildings of The London Cancer Hub, which will create new anti-evolution therapies and enhance its ability to partner with industry to take them to market.
Our research partnerships
As well as ranking as the UK’s leading higher education institution for the quality and impact of our research, the ICR is also the most successful at commercialising its discoveries, in order to take new treatments to patients.
The ICR was recently ranked third among the world’s higher education institutes (HEIs) for the rate of citation of its published scientific research, and also as the top HEI globally on two measures of interaction with industry.
It has more than 100 active partnerships with a range of companies, from small, specialised biotech and medtech firms to big pharma, and is consistently ranked by international league tables as one of the world’s most successful higher education institutions for effective collaboration with industry.
Professor Paul Workman said:
“Collaborations between researchers at UK universities and industry partners are part of the lifeblood of a thriving life-science industry, and play a major role in the discovery and development of the new drugs, biomarkers and devices that make the biggest difference to the lives of people with cancer across the world.
“The UK academic sector performs a crucial, innovative function in driving these partnerships and our fundamental research discoveries underpin so much of the translational research that goes on to transform healthcare and generate commercial success as well.
“As both an academic leader and entrepreneur, I feel that it’s very important for me to emphasise that London and the UK generally are open for business – in terms of both academic and industry partnerships.
“The ICR is very happy to be working with MedCity to further develop the UK’s growing relationship with Japan, and the associated opportunities for breakthroughs in cancer research. It is a fantastic opportunity to showcase The London Cancer Hub, which aims to be a global centre for cancer innovation – bringing together researchers, clinicians and the commercial sector so they can collaborate closely in creating exciting new innovations to defeat cancer.